Kedem is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has developed a new formulation for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with less drug breakdown in the liver or gastrointestinal system, a process that can reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In human studies, X-Excite has been shown to reach the blood stream faster than the oral route of delivery. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include anti-stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.